Millbury, MA, United States
Millbury, MA, United States

Time filter

Source Type

MATRAN, Switzerland, November 1, 2016 /PRNewswire/ -- Piramal Imaging S.A. today announced that it has received Shonin (medical device) approval from the Ministry of Health, Labor and Welfare (MHLW) of Japan for Neuraceq Automated Synthesizer Synthera® (Neuraceq自動合成装置 Synthera®). The...


News Article | December 13, 2016
Site: globenewswire.com

IBA signs two new Proteus®ONE contracts with Proton Partners International Louvain-La-Neuve, Belgium, 13 December 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed two new contracts with Proton Partners International (PPI), to install two Proteus®ONE* compact proton therapy solutions in Reading and an undisclosed site in the UK. The contracts are effective as of today. The contracted Proteus®ONE solutions include Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities making Proteus®ONE the only compact solution ready for adaptive treatment. The contracts also include a maintenance agreement. The typical end-user price for a Proteus®ONE solution with a maintenance contract is between EUR 35 and 40 million. These new centers will be the fifth and sixth that IBA will install for PPI. Previously-ordered centers by PPI are currently being installed in Wales (Newport), in England (Northumberland and London) and in Abu Dhabi, UAE. These latest contracted Proteus®ONE will be the 15th and 16th installation of IBA's compact single-room proton therapy solution, globally. IBA has now sold 45 proton therapy centers worldwide. These projects are a result of the framework agreement with Philips that has been in place since September 2014, demonstrating the benefit of this relationship in bringing new international contracts to fruition. Olivier Legrain, Chief Executive Officer of IBA, commented: "We are delighted to partner with PPI, the institution that leads proton therapy penetration in UK and in the United Arab Emirates. PPI's choice of IBA and our compact solution demonstrates the increasing demand for this cutting edge treatment modality. At present, proton therapy represents only 1% of all radiotherapy treatments, however, studies estimate that 20% of patients treated by radiotherapy would benefit from being treated with proton therapy." Mike Moran, Chief Executive Officer of Proton Partners International Limited, added: "We are very pleased to further expand our collaboration with IBA following the highly professional support and responsiveness that it has demonstrated to date. Cancer incidence is rising dramatically, globally, and more innovation is needed to deal with this disease. Our strategy of building a strong international network of proton therapy centers will guarantee high-quality treatment throughout our network, enabling more patients to benefit from cutting-edge proton therapy. Every cancer patient in UK deserves the best possible care without needing to travel far." About Proteus®ONE Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus®ONE makes proton therapy easy. * Proteus®ONE is the brand name of Proteus®235 in the US and Europe and a certified product in Japan. About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com About Proton Partners International Limited Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation's cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company. Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical officer to the company. The Welsh Government's Life Sciences Investment Fund is a key investor in Proton Partners International. For more information on Proton Partners, please visit: www.proton-int.com For further information, please contact:


Piramal Imaging S.A. today announced that it has received Shonin (medical device) approval from the Ministry of Health, Labor and Welfare (MHLW) of Japan for Neuraceq Automated Synthesizer Synthera® (Neuraceq自動合成装置 Synthera®). The approval, obtained through Piramal Imaging's service partner, SCETI K.K., Tokyo, enables Japanese hospitals and imaging centers access to the equipment needed for on-site manufacturing of the β-amyloid imaging agent florbetaben 18F, which is approved in the EU, U.S. and South Korea under the brand name Neuraceq™. "The availability of Neuraceq Automated Synthesizer Synthera® (Neuraceq自動合成装置 Synthera®) will contribute to further advance public health in Japan by assisting in the diagnosis of Alzheimer's disease and other forms of dementia, a growing concern in the Japanese society," said Dr. Ludger Dinkelborg, Director of the Board, Piramal Imaging. "In addition to expanding the market reach for Neuraceq™, the Shonin approval for Neuraceq Automated Synthesizer Synthera® (Neuraceq自動合成装置 Synthera®) supports our ambition of making this important diagnostic tool available on a global scale to the expanding population facing dementia", Dinkelborg added further. Neuraceq Automated Synthesizer Synthera® (Neuraceq自動合成装置 Synthera®) is a medical device manufactured by IBA, SA RadioPharma Solutions, Belgium. MHLW has approved the device, IBA Synthera® V2, as the manufacturing platform for the in-house production of florbetaben 18F solution for Japanese hospitals. Florbetaben 18F, made on Neuraceq Automated Synthesizer Synthera® platform (Neuraceq自動合成装置 Synthera®), is a radioactive diagnostic agent approved in Japan for visualization of brain beta-amyloid plaques in patients with cognitive impairment suspected to have Alzheimer's disease. Florbetaben 18F binds to neuritic beta-amyloid plaques in the human brain, a hallmark characteristic of Alzheimer's disease, a condition that slowly destroys memory and cognitive abilities and currently affects over 46 million people worldwide[1]. Until today, an estimated 20-30% of patients with dementia[2] have been misdiagnosed and often experience extended diagnostic episodes before receiving a clinical diagnosis. A definitive diagnosis of Alzheimer's disease can only be made after death based on autopsy findings of beta-amyloid plaques and neurofibrillary tangles in the brain. Today, a comprehensive clinical evaluation in combination with in-vivo biomarkers, such as beta-amyloid PET imaging, improves the diagnostic accuracy, allowing for improved patient management. Recently, Piramal Imaging submitted a Summary Technical Document (STED) medical device dossier to the Pharmaceutical and Medical Devices Agency (PMDA) seeking approval for Neuraceq Automated Synthesizer Synthera® (Neuraceq自動合成装置 Synthera®). Under the Shonin approval process, Neuraceq Automated Synthesizer Synthera® (Neuraceq自動合成装置 Synthera®) is approved as a radioactive-material medical-treatment instrument (category: Equipment 10), with the general designation of radiopharmaceutical synthetic equipment (70009000), Class III. The device is to be distributed to Japanese hospitals by SCETI K.K., Tokyo, who will also train hospital personnel on its use. Indication Neuraceq™ is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. A negative Neuraceq™ scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq™ scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq™ is an adjunct to other diagnostic evaluations. Piramal Imaging S.A., a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine. Piramal Imaging strives to be a leader in the molecular imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. For more information please go to http://www.piramal.com/imaging. A pioneer among foreign companies in Japan, SCETI was established in Tokyo in 1925, before it joined Denis Group in 1952. In its early years, the company served as agent for major French Heavy Industry companies. Along the way, SCETI became gradually involved in nuclear medicine, strengthening its portfolio in quantum equipment, isotopes, reagents and diagnostics. Meanwhile, it diversified its activities into Life Sciences importing advanced functional ingredients for food, health-food, cosmetics and pharmaceuticals manufacturing. Lately, the company ventured into medical imaging distributing high-end systems, equipment & services used in medical diagnosis and treatment. As of today, SCETI markets innovative Health Science solutions focusing on Life Sciences, Medical and Bio-Medical. It works as importer, distributor and licensor operating under QMS compliance. It serves the Industrial, Medical, Clinical, Pharmaceutical and Research networks in Japan and export markets. Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality production equipment, IBA has developed in-depth experience in setting up GMP-compliant radiopharmaceuticals production centers. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: http://www.iba-worldwide.com [] Alzheimer's Disease International. World Alzheimer Report 2015, The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf, (accessed Sept 15, 2016) [2] Beach TG, Monsell SE, Phillips LE, Kukull W Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J. Neuropathol. Exp. Neurol. 71(4),266- 73 (2012).


News Article | December 15, 2016
Site: globenewswire.com

Louvain-la-Neuve, Belgium, December 15, 2016 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises and cancellations of stock options) dated December 15, 2016. Data concerning transparency Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008 Communication of the basic data as per Article 15 §1 al.1 of the Law Communication of the additional data as per Article 15 §1 al.2 of the Law Statutory thresholds as per Article 18 of the Law The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent. About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com . For more information, please contact IBA Caroline Hardy Corporate Legal Counsel +32 10 201 159 caroline.hardy@iba-group.com


Cleland M.R.,IBA Inc | Stichelbaut F.,Ion Beam Applications IBA
Radiation Physics and Chemistry | Year: 2013

The radiation processing of materials and commercial products with high-energy X-rays, which are also identified by the German term bremsstrahlung, can produce beneficial changes that are similar to those obtained by irradiation with nuclear gamma rays emitted by cobalt-60 sources. Both X-rays and gamma rays are electromagnetic radiations with short wavelengths and high photon energies that can stimulate chemical reactions by creating ions and free radicals in irradiated materials. Nevertheless, there are some physical differences in these energy sources that can influence the choice for practical applications. The English translation of bremsstrahlung is braking radiatiorn or deceleration radiation. It is produced when energetic electrons are deflected by the strong electric field near an atomic nucleus. The efficiency for producing this kind of electromagnetic energy increases with the kinetic energy of the electrons and the atomic number of the target material. The energy spectrum of the emitted X-ray photons is very broad and extends up to the maximum energy of the incident electrons. In contrast, a cobalt-60 nucleus emits two gamma rays simultaneously, which have well-defined energies. Another significant difference is the angular distribution of the radiation. Nuclear gamma rays are emitted in all directions, but high-energy bremsstrahlung photons are concentrated in the direction of the incident electrons when they strike the target material. This property enables an X-ray processing facility to be more compact than a gamma-ray processing facility with similar throughput capacity, and it increases the penetration and the efficiency for absorbing the emitted X-ray energy in the irradiated material. Recent increases in the electron energy and the electron beam power from modern industrial accelerators have increased the throughput rates in X-ray processing facilities, so that this irradiation method is now economically competitive with large cobalt-60 facilities. Several industrial facilities are now equipped to provide radiation processing with X-rays. This paper describes the characteristics of high-energy, high-power X-rays, and some practical applications in curing polymeric materials with this kind of radiation. © 2012 Elsevier Ltd.


News Article | February 20, 2017
Site: globenewswire.com

IBA Selected to Install New Proton Therapy Center in Charleroi, Belgium New Proteus®One installation to be dedicated to research and development in collaboration with the Wallonia Region government and four leading Belgian universities Louvain-la-Neuve, Belgium, February 20, 2017 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has been selected as the preferred vendor by four leading universities of Brussels (ULB), Liège (Ulg), Mons (UMons) and Namur (UNamur), alongside the Wallonia Region government, to install a Proteus®ONE* solution, IBA's single-room compact proton therapy system, in Charleroi, Belgium. IBA was selected following a comprehensive European public tender process and expects to sign a final contract in the coming weeks, after expiration of the applicable waiting period. The new center will be dedicated primarily to the research and development of new proton therapy applications and techniques in order to extend the range of proton therapy used in the treatment of cancer. The center, which will also treat patients, will be located in Charleroi and is expected to be operational in 2020. The Wallonia Region will invest a total of EUR 47 million in this research project, which will include the IBA technology, research program, maintenance contract as well as related equipment. Olivier Legrain, Chief Executive Officer of IBA commented: "We are delighted to have been selected to build a proton therapy center dedicated to R&D, demonstrating that Belgium has all the scientific, clinical and technological expertise required to advance this significant technology in the fight against cancer. Not only will this research and development center enable IBA and the Belgian universities to test and develop new generation technologies to fight cancer, it will also develop and anchor industrial expertise shared by a network of local companies. We are committed to supporting these universities in providing high-quality cancer treatment to more patients in Belgium." About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE is a brand name of Proteus 235 For further information, please contact:


News Article | December 6, 2016
Site: www.prnewswire.co.uk

Software Magazine Ranks IBA Group as one of the World's Largest Software Companies in 2016 IBA Group http://www.ibagroupit.com announces its inclusion in Software Magazine's Software 500 ranking of the world's largest software and service providers, now in its 34th year. IBA Group was ranked #281 (301 in 2015), with a total software and services revenue of US$110.85 million. IBA Group has been selected for Software 500 since 2008 when the company applied for inclusion for the first time. The Software 500 is a revenue-based ranking of the world's largest software and services suppliers, targeting medium to large enterprises, their IT professionals, software developers, and business managers involved in software and services purchasing. The ranking is based on total worldwide software and services revenue from the 2015 fiscal year. Suppliers are not ranked on total corporate revenue, since many, like IBA Group have other lines of business, such as hardware. According to Software Magazine, the total software and service revenue for the 2016 Software 500 reached $705.8 billion, down 5.7 percent from $748.7 billion reported in the 2015 Software 500. Now in its 34th year, the Software 500 provides a detailed look at changes in the software industry from a revenue, employee, and research and development (R&D) perspective. The top growth areas include business process management, social analytics, and database/data management, all offering an average growth per company above 50 percent over the 2015 fiscal year. See the 2016 Software 500 ranking at http://rcppubs.com/3D/SWM/2016/nov/index.html IBA Group is one of the largest IT service providers in Eastern Europe. Headquartered in Prague, Czech Republic, IBA Group has offices and development centers in the United States, Great Britain, Germany, Czech Republic, Belarus, South Africa, Cyprus, Russia, Ukraine, Kazakhstan, and Slovakia. IBA Group focuses on mainframe systems, enterprise applications, web solutions, SAP, business analytics, and mobile applications. IBA Group is recognized by the International Association of Outsourcing Professionals (IAOP) as one of The Global Outsourcing 100 in the Leaders Category, and ranks as one of the world's largest software companies in the Software Magazine's Software 500. The company is a winner of the Award for Corporate Social Responsibility in 2016 GSA Awards organized by Global Sourcing Association. In 2015, 2014, 2012, and 2011, IBA Group won IT Europa's European IT & Software Excellence awards. For more information, visit http://ibagroupit.com


News Article | November 16, 2016
Site: globenewswire.com

Louvain-La-Neuve, Belgium, 16 November 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces its trading update for the third quarter ending 30 September 2016. Olivier Legrain, Chief Executive Officer of IBA commented: "This has been another positive quarter of growth, driven by continued robust demand in the global proton therapy market and timely execution of the backlog. With a growing order book from markets as diverse as Europe, US, China and the UAE, we are confident about the outlook of the Company, despite challenges in the dosimetry market which has further decreased as a proportion of our overall business. We are continuing to make targeted strategic investments in our business to ensure that we can maintain and grow our clear leadership in proton therapy, expanding our product offering to provide greater choice to customers and investing in our commercial, manufacturing and service capabilities." IBA reported the following segmental trends and news during the third quarter of 2016: IBA currently anticipates full-year revenue growth of around 20%, with continued strong PT performance more than offsetting current weakness in the Dosimetry market. Due to a lower than expected Dosimetry profit margin for the year, the operating margin is expected to be around 10%, slightly below previous expectations of around 11%, before rising to between 13% and 15% by 2018. Achievement of these targets depends on the timing of a small number of outstanding additional PT contracts. The Company is making a number of strategic investments in order to build on and expand its leadership in the global PT market. This includes scaling up production capacity including a new Proteus®ONE accelerator (S2C2) assembly line, plus additional investment in R&D and commercial infrastructure. Total CAPEX is expected to be around EUR 15 million, of which about EUR 2.5 million will be in 2016, with the remainder in 2017 and 2018. The Company is also focusing on additional skilled recruitment to meet growing market demand, with the remainder of the additional 400 engineers and other qualified staff expected to take the total headcount to around 1,600 by the end of 2016. This additional recruitment is expected to be largely self-financing through rapid revenue generation. IBA expects to maintain the dividend pay-out ratio at 30%. In accordance with the Royal Decree of 14 November 2007, IBA indicates that this Trading Update has been prepared by the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO). About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE and Proteus®PLUS are the brand names of new configurations of the Proteus®235. For further information, please contact: IBA Jean-Marc Bothy Chief Strategy Officer Soumya Chandramouli Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com


Jongen Y.,IBA Inc
CYCLOTRONS 2010 - 19th International Conference on Cyclotrons and Their Applications | Year: 2010

The science and technology of proton and carbon therapy was initially developed in national and university laboratories. The first hospital based proton therapy facility was built at Loma Linda University with the help from Fermilab. After this initial phase, and starting with the tender for the proton therapy system at MGH, many proton and carbon beam facilities have been ordered from industry and built. Industrially made proton and carbon therapy facilities represent today the vast majority of the installed base.


News Article | December 6, 2016
Site: www.prnewswire.com

PRAGUE, December 6, 2016 /PRNewswire/ -- Software Magazine Ranks IBA Group as one of the World's Largest Software Companies in 2016 IBA Group http://www.ibagroupit.com announces its inclusion in Software Magazine's Software 500 ranking of the world's largest software and service...

Loading IBA Inc collaborators
Loading IBA Inc collaborators